A twice-yearly injection could revolutionise HIV prevention. But who gets access raises bigger questions about public money, pharmaceutical power, drug prices and shrinking global health funding. Al Jazeera’s @itsmikailmalik looks at the fight over access. https://t.co/hrtDteJU0P